This article is a placeholder indicating that it is an earnings preview for Cytokinetics. It simply states that Cytokinetics will report its financial...
Neutral
Cytokinetics announced inducement grants under Nasdaq Listing Rule 5635(C)(4). This brief article from Refinitiv states that the information is copyri...
Neutral
Cytokinetics (CYTK) insiders, including the President & CEO and EVP & CCO, recently sold shares totaling approximately $982,132. These sales took plac...
Bearish
Andrew Callos, Executive Vice President, Chief Commercial Officer at Cytokinetics Inc (CYTK), sold 7,449 shares of the company on April 15, 2026. This...